1	
2	RNA modifications regulating cell fate in cancer
3	
4	Sylvain Delaunay ¹ and Michaela Frye ^{1,2} *
5	
6	
7	¹ University of Cambridge, Department of Genetics, Downing Street, Cambridge CB2 3EH,
8	UK, ² German Cancer Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg,
9	Germany
10	
11	*Correspondence to: mf364@cam.ac.uk; m.frye@dkfz-heidelberg.de
12	
13	
14	Abstract
15	The deposition of chemical modifications into RNA is a crucial regulator of temporal and
16	spatial accurate gene expression programs during development. Accordingly, altered RNA
17	modification patterns are widely linked to developmental diseases. Recently, the
18	dysregulation of RNA modification pathways also emerged as a contributor to cancer. By
19	modulating cell survival, differentiation, migration, and resistance, RNA modifications add a
20	novel regulatory layer of complexity to most aspects of tumourigenesis.
21	

22 Post-transcriptional RNA modifications

23 Currently, over 170 RNA modifications are known, and most RNA species contain one or multiple distinct chemical modifications¹. Determining the function of these modifications in 24 25 RNA metabolism requires their reliable detection at single-nucleotide resolution. Only a 26 handful of modifications can be mapped at high resolution using high throughput (HTP) sequencing technologies². However, these newly developed technics have revealed that RNA 27 28 modifications modulate most steps of gene expression from RNA transcription to protein 29 translation. Here, we will focus on recently discovered regulatory functions of RNA 30 modifications and discuss their emerging roles in regulating cell fate in normal tissues and 31 cancer.

32

33 Protein synthesis occurs at the ribosome and involves the translation of the messenger RNA 34 (mRNA) into amino-acids via transfer RNAs (tRNA). Ribosomal RNA (rRNA) is the most 35 abundant type of RNA in a cell. Around 130 individual rRNA modifications have recently been visualized in the three-dimensional structure of the human ribosome 3 . The most 36 37 abundant rRNA modifications in eukaryotes are 2'-O-methylation of the ribose and the isomerisation of uridine to pseudouridine (Ψ)⁴. Most rRNA modifications occur in or close 38 39 to functionally important sites and can facilitate efficient and accurate protein synthesis when they occur for instance at the peptidyltransferase center and the decoding site 3,4 . 40

41

Tens of millions of tRNA transcripts occur in a human cell, and tRNA is the most modified RNA in a cell ⁵. The modifications are highly diverse, and their functions depend on the location within a tRNA and its chemical nature (*Figure 1a*). The most common tRNA molecules consist of 76 nucleotides ⁶. A human tRNA contains between 11 to 13 different modifications ⁷. Accordingly, a large number of enzymes are involved in the site-specific

47 deposition of the modifications (*Figure 1a*). The modifications range from simple 48 methylation or isomerization events, such as m^5C , m^1A , Ψ , 5-methyluridine (m^5U), 1- and 49 1/7-methylguanosine (m^1G , m^7G), and inosine, to complex multistep chemical modifications, 50 such as N6-threonylcarbamoyladenosine (t^6A) and 5-methoxycarbonylmethyl-2-thiouridine 51 (mcm⁵s²U)⁵.

52

The most abundant internal modification in mRNA (and also long non-coding RNA) is N6methyladenosine (m⁶A) ⁸⁻¹¹. Around 0.1 to 0.4% of all mRNA adenines are methylated, representing approximately 3-5 modifications per mRNA ¹¹⁻¹³. Other rarer modifications within eukaryotic mRNA include N1-methyladenosine (m¹A), N6-2'O-dimethyladenosine (m⁶A_m), 5-methycytosine (m⁵C), 5-hydroxymethylcytosine (hm⁵C), and pseudouridine (Ψ) (*Figure 1b*) ¹⁴⁻²¹. Some of these modifications are generated by stand-alone enzymes ²², others are installed by multi-protein writer complexes and accessory subunits (*Figure 1b*) ²³.

60

61 RNA modifications modulate gene expression programs

The first step of gene expression is the transcription of DNA molecules into mRNA. The deposition of m⁶A into nascent pre-mRNA is carried out in the nucleus by a multicomponent methyltransferase complex 24,25 . The multi-protein writer complex installing m⁶A consists of the Methyltransferase Like catalytic subunits (METTL3, METTL14), and many other accessory subunits 23 . Gene-specific transcription factors and chromatin modifying enzymes can further modulate the deposition of m⁶A into nascent RNA by repelling or recruiting the m⁶A writer complex $^{26-28}$.

Two demethylases, Fat Mass and Obesity-associated protein (FTO) and AlkB Homolog 5 (ALKBH5) act as erasers of the m⁶A modification (*Figure 2a*) 29,30 . Several reader proteins

selectively bind m⁶A containing mRNAs. For instance, binding of YTH N6-Methyladenosine RNA Binding Protein 2 (YTHDF2) targets the transcripts for degradation $^{31-34}$. Recruitment of YTHDF1/3 enhances translation (*Figure 2a*) 35,36 . The deposition of m⁶A and other additional mRNA modifications contribute to most aspects of RNA metabolism such as transcript stability, pre-mRNA splicing, polyadenylation, mRNA export, and translation 23,37,38 .

78

79 The second major step in gene expression is mRNA translation. Multiple aspects of protein 80 synthesis are differently regulated among somatic cells and thereby contribute to cell identity and function within tissues ³⁹. Eukaryotic cells rely on the tight control of mRNA translation 81 82 to quickly respond to a changing micro-environment, including nutrient deprivation and stress, development and differentiation, and cancer ³⁹⁻⁴¹. All three main types of RNAs 83 84 involved in translation (mRNA, tRNA and rRNA) are highly modified in mammals, and their 85 interaction with the respective modifying enzymes often results in qualitative and quantitative changes of protein synthesis ^{4,5,23}. 86

87

88 tRNA modifications modulating mRNA translation

89 Transfer RNAs have multiple and versatile functions in regulating gene expression. To 90 decode only 20 amino acids, the human genome encodes at least 610 tRNAs that are often tissue-specifically expressed ⁴²⁻⁴⁴. All tRNAs carry modifications, but the extent of 91 92 modifications in individual tRNAs varies and mitochondrial tRNAs are generally less modified, containing on average of five modifications per molecule ⁵. The diversity of 93 94 modifications together with their highly similar L-shaped fold gives tRNAs the propensity to 95 interact with a large number of RNAs and proteins during translation to modulate protein 96 synthesis rates ⁴⁵.

97

98 RNA modifications can occur along the whole L-shape of the tRNA, yet they are the most 99 diverse at the wobble position, where they often optimize codon usage during gene-specific translation (Figure 1a; C34 pink)⁴⁶⁻⁴⁸. For example, uridines in position 34 of the wobble 100 base of tRNA^{UUU}, tRNA^{UUC}, tRNA^{UUG} and tRNA^{UCU} can contain a 5-carbamoylmethyl 101 (ncm^5) or 5-methoxycarbonylmethyl-2-thiouridine (mcm^5s^2) side-chains. This requires the 102 103 successive activities of the conserved acetyltransferase six-subunit Elongator complex, the 104 methyltransferase ALKBH8, and the thiouridylase CTU1/CTU2, together with the URM pathway (Ubiquitin-Related Modifier pathway) (Figure 2b)^{49,50}. The wobble modification 105 enhances base-pairing and protein translation of mRNAs enriched for the corresponding 106 codons⁴⁹⁻⁵¹. Loss of the modification leads to codon-specific translation pausing of the 107 ribosomes 52,53. 108

109

Cytosine-5 methylation (m⁵C) occurs in the anti-codon loop and the variable arm of tRNAs 110 (*Figure 1a*) ⁵⁴. The methyltransferase NSUN3 is required for the formation of m^5C at the 111 wobble position in mitochondrial tRNA for start methionine (tRNA^{Met}) ^{55,56}. NSUN3-112 dependent deposition of m⁵C is required to initiate the subsequent biogenesis of 5-113 114 formylcytidine (f⁵C), which is mediated by the RNA dioxygenase AlkB Homolog 1 (ALKBH1) ⁵⁵⁻⁵⁸. Consequently, loss of these modifications due to deletion of NSUN3 115 116 inhibits mitochondrial protein translation and impairs mitochondrial functions. Other modifications that occur in the anticodon loop, but not at the wobble position, such as t⁶A at 117 position 37 and m⁵C at position 38 modulate translation elongation rates and fidelity 118 respectively 59,60. 119

121 Modifications outside the anticodon loop are often implicated in tRNA processing and cleavage. Deposition of m^5C and Ψ modulates the biogenesis of tRNA-derived small non-122 coding RNA fragments (tRFs)⁶¹⁻⁶³. Loss of NSUN2-mediated methylation at the variable 123 loop increases the affinity to the endonuclease angiogenin, and thereby promotes cleavage of 124 tRNAs into tRFs, which then inhibit global protein synthesis (*Figure 2c*) 54,64 . The deposition 125 126 of Ψ by PUS7 also influences the biogenesis of tRFs; yet interestingly, loss of PUS7 leads to increased protein biosynthesis ⁶². Deposition of Queuosine (Q) at the wobble anticodon 127 position of tRNAs protects against ribonuclease cleavage ⁶⁵, and Q-tRNA levels promote 128 DNMT2-mediated methylation ⁶⁶. Together, m⁵C and Q control translational speed of Q-129 decoded codons as well as at near-cognate codons ⁶⁶. Loss of DNMT2-mediated methylation 130 131 at the anti-codon loop (C38) causes tRNA-specific fragmentation and codon-specific mistranslation ⁶⁰. Depletion of queuine, the precursor for Q, which is provided through the 132 133 diet and gut microbiota, results in unfolded proteins triggering the endoplasmic reticulum stress response 66. 134

135

In summary, in response to environmental cues, tRNA modifications can act as a rheostat of protein synthesis rates via at least two mechanisms. First, modifications outside the anticodon loop often modulate the rate of *de novo* protein synthesis. Second, modifications within the anticodon loop can determine the translation speed of codon-specific genes. Because wobble base modifications usually affect gene-specific translation, they have the potential to directly modulate distinct cellular functions such as survival, growth or differentiation.

142

143 The regulatory potential of RNA modifications in cancer

Due to their ability to modulate many aspects of RNA metabolism and influence protein
 synthesis rates, several RNA modifications emerged as important regulators in cancer ^{51,67,68}.

146 Similar to normal tissues, also a tumour contains functionally and phenotypically different 147 cell populations. Tumour heterogeneity is the consequence of genetic change, environmental differences, and reversible changes in cellular properties ⁶⁹. The heterogenous cell 148 149 populations are not equally tumourigenic. Some cancer cells are more differentiated with a 150 limited tumorigenic potential. Others, potentially even rare tumour populations, exhibit stem cell-like features that drive tumourigenesis, long-term survival, and therapy resistance 70 . 151 152 While RNA modifying-enzymes are generally not considered to be cancer driver genes, they 153 have been functionally linked to sustain cell survival, proliferation, growth or differentiation 154 of tumour-initiating cells. Abnormal expression of RNA modifying enzymes can reduce the tumour cell's sensitivity towards differentiation cues (m⁶A, m⁵C) or sustain the expression of 155 156 specific genes required for proliferation, invasion and resistance to anti-cancer drugs $(mcm^{5}s^{2}U, m^{6}A, m^{5}C).$ 157

158

159 RNA modifications regulating the fate of tumour-initiating cells

Members of the mcm ${}^{5}s^{2}U$ writer complex are upregulated in melanoma as well as colon and 160 breast cancer ⁷¹⁻⁷³. ELP3, the catalytic subunit of the Elongator complex, is required for Wnt-161 driven intestinal tumour initiation ⁷². Deletion of ELP3 in Lgr5⁺ tumour initiating cells delays 162 tumor growth, yet the number of $Lgr5^+$ cells remains unchanged ^{72,74}. Thus, the correct 163 164 formation of mcm⁵s²U promotes the tumourigenic potential of specific cell populations 72 . A 165 cell type-specific function of ELP3 can be explained by the codon-specific effect of mcm⁵s²U 166 on translation. For instance, in colon cancer cells, ELP3 promotes translation SOX9, a downstream target of Wnt/β-catenin signaling ^{72,75}. In breast cancer, ELP3 enhances translation of 167 the DEK proto-oncogene, whose mRNA is enriched for mcm^5s^2U sensitive codons ⁷¹. 168 169

A cell type-specific functional requirement of $mcm^{5}s^{2}U$ is also exemplified in development. 170 171 While Elongator is required for the brain, it is dispensable for the formation of intestine and mammary glands ^{71,72,76-78}. Loss of ELP3 in the developing brain leads to microcephaly. 172 Ribosome profiling in the mutant forebrain revealed enhanced pausing at putative mcm⁵s²U 173 174 sites. These codon-specific translation defects may cause an accumulation of unfolded or 175 misfolded proteins and thereby explain the activation of the endoplasmic reticulum (ER) stress response, leading to the activation of the Unfolded Protein Response (UPR) pathway 76 . 176 177 In contrast, melanoma and breast cancer cells fail to activate the UPR pathway, again indicating that mcm 5 s²U modification exerts cell context-specific functions 71,79 . 178

179

The deposition of m⁵C by NSUN2 is also required for normal development and implicated in 180 cancer ^{64,80-84}. Loss of the *NSUN2* gene causes growth retardation and neuro-developmental 181 deficits in human and mice 54,80-82. In cutaneous tumours, NSUN2 is absent in tumour-182 183 initiating cells but highly expressed in committed progenitor populations. Accordingly, deletion of NSUN2 increases the number of tumour-initiating cells (*Figure 3*) 64 . As 184 185 described for some tissue stem cells, also tumour-initiating cells of skin tumours are 186 functionally maintained by low protein synthesis rates, which is at least in part maintained by tRFs in the absence of NSUN2^{64,85-87}. Thus, similar to the cellular response to stress or 187 injury, in which global protein synthesis is commonly reduced ⁸⁸, tumour-initiating cells may 188 189 also require low translation rates to alleviate cellular damage and increase longevity and 190 survival rate.

191

192 The correct deposition of m^6A into mRNA is essential for embryo development and cell 193 differentiation due to its role in governing the stability of key regulatory transcripts ²³. 194 Complete absence of m^6A due to deletion of METTL3 is early embryonic lethal due to the 195 extended transcript lifetime of key pluripotency regulators (e.g. Nanog, Sox2, and Klf4) and the inability to start differentiation programs (*Figure 2a*) 89,90 . Thus, the deposition of m⁶A 196 197 affects the stability of distinct groups of transcripts, for instance pluripotency factors, 198 allowing their synchronized regulation. This coordination of RNA metabolism then allows 199 the cell to transit through specific cell states, such as self-renewal, proliferation or 200 differentiation, in response to cellular signaling and environmental cues. These 201 environmental cues may include growth factors, cytokines, or external stress factors (e.g. 202 hypoxia, oxidative stress, or injury). Such a mechanism allowing the fast adaptation to 203 changing micro-environments is also required in tumours (Figure 3).

204

Increased levels of m⁵C and m⁶A in RNA was first reported in circulating tumour cells of lung cancer patients by mass spectrometry ⁹¹. However, several studies then showed that m⁶A de-methylation promotes proliferation and tumourigenesis in different types of cancer. Hypoxia-induced up-regulation of ALKBH5 in breast cancer cells decreased m⁶A and enhances mammosphere formation ⁹². ALKBH5 is also highly expressed in glioblastoma and sustains the proliferation of patient-derived glioblastoma cells ⁹³.

The m⁶A de-methylase FTO is highly expressed in patients with acute myeloid leukemia 212 (AML) ⁹⁴. FTO enhances leukemic oncogene-mediated cell transformation and 213 214 leukemogenesis by promoting cell proliferation and survival and inhibiting all-trans-retinoic acid (ATRA)-induced AML cell differentiation ⁹⁴. Knockdown of METTL3 or METTL14 215 216 also promotes tumourigenesis of primary human glioblastoma cells in vitro and in vivo, an effect that was reverted by overexpression of METTL3 or inhibition of FTO 95. Similarly, R-217 218 2-hydroxyglutarate (R-2HG), an oncometabolite that inhibits FTO, also exerts an antileukemic activity in vitro and in vivo 96. Treatment with R-2HG increased m⁶A leading to 219

degradation of *Myc/Cebpa* transcripts and suppression of the relevant down-stream pathways
 ⁹⁶. Finally, 70% of endometrial tumours exhibit m⁶A reduction, either attributed to METTL14
 mutation or METTL3 downregulation ⁹⁷. Low levels of m⁶A enhances proliferation and
 tumorigenesis of endometrial cancer cells, through AKT signaling pathway ⁹⁷.

224

225 Unexpectedly, the m⁶A methyltransferase METTL3 is also more abundant in AML cells 226 when compared to healthy CD34-positive stem and progenitor hematopoietic cells ⁹⁸, and is essential for the growth of acute myeloid leukaemia cells ^{28,98}. Downregulation of METTL3 227 228 or METTL14 causes cell cycle arrest and differentiation of leukaemic cells through 229 transcriptional repression of distinct sets of transcripts, such as genes containing a CAATT-230 box binding protein at the transcription start site in the absence of METTL3 and Myb and Myc in the absence of METTL14^{28,99}. Together, these studies indicate that elevated levels of 231 232 m⁶A is advantageous for the maintenance of an undifferentiated cell state in leukemia. Similarly, METTL3 promotes growth, survival, and invasion of human lung cancer cells ¹⁰⁰. 233 234 Yet in this study, METTL3 promoted translation of certain mRNAs (e.g. Egfr and Taz) 235 through association with ribosomes in the cytoplasm, this function was independent of its catalytic activity and m⁶A readers ¹⁰⁰. The m⁶A reader Insulin-like growth factor 2 mRNA-236 237 binding proteins (IGF2BP) also promotes mRNA stability and translation of its target mRNAs, for example M_{VC} (*Figure 2a*)¹⁰¹. 238

239

Together, these studies reveal that aberrant methylation and de-methylation of mRNA influences tumour initiation and growth. The precise underlying mechanisms how both m⁶A methylases and de-methylases can promote tumourigenesis remain unclear. However, methylation and de-methylation events occur on distinct and often cell-state specific key regulatory transcripts at gene-specific regions ¹⁰². In addition, these sets of transcripts are likely to differ in stem cells and undifferentiated or committed progenitors. Thus, depending
on the cell of origin of the respective tumour and the identity of the distinct driver mutations,
the degradation or stabilization of distinct sets of mRNAs may confer growth advantages.
Finally, tumours are highly heterogeneous and the distinct tumour populations may be more
or less sensitive to changes in m⁶A levels.

250

251 RNA modifications regulating tumour invasion and metastasis

252 Phenotypic transitions between cell states also occurs in cancer and include epithelial-to-253 mesenchymal transition (EMT), cancer stem-like properties, metabolic reprogramming, the 254 emergence of therapy resistance, and programmed cell death. RNA modifying enzymes are 255 often required for cell survival in response to external stress stimuli (e.g. UV-radiation and oxidative stress)¹⁰³. Tumour cells are constantly exposed to a hostile microenvironment, due 256 257 to shortage of oxygen and nutrients; and hypoxia-induced gene activity is crucial for tumour metastasis ^{104,105}. Although hypoxia can dynamically change tRNA modifications ¹⁰⁶, their 258 259 precise functional roles during tumour cell invasion and metastasis is unclear.

260

Several mcm⁵s²U writers are upregulated in cells undergoing EMT, and ELP3 promotes translation of LEF1 to sustain metastasis in invasive breast cancer mouse models ⁷¹. Cellular migration and invasion is impaired in the absence of NSUN2 *in vitro* ^{64,107,108} and tRNAderived cleavage products have been shown to modulate the metastatic potential of breast cancer cells ¹⁰⁹.

267 The m⁶A writer METTL3 enhances translation initiation of certain mRNAs including 268 epidermal growth factor receptor (EGFR) and the Hippo pathway effector TAZ, and thereby 269 promotes growth, survival, and invasion of human lung cancer cells (*Figure 3*) ¹⁰⁰. METTL3

has been also described to promote liver cancer progression through an YTHDF2-dependent
 mechanism and knockout of METTL3 suppressed tumorigenicity and lung metastasis *in vivo* ¹¹⁰.

273

Conversely, down regulation of METTL14 enhances metastasis in hepatocellular carcinoma (HCC) ¹¹¹. Both METTL3 and METTL14 have been described to modulate the microRNA (miRNA)-guided RNA silencing pathway ^{111,112}. METTL3 methylates pri-miRNA and marks them for recognition and processing by the microprocessor complex subunit DCR8 ¹¹².
Similarly, METTL14 interacts with DGCR8 to enhance miR126 processing, a miRNA associated with invasive potential of HCC cell lines ¹¹¹.

280

281 **RNA** modifications regulating drug resistance

282 Several recent studies demonstrated a link between RNA modifications and tumour cell 283 survival in response to chemotherapeutic drug treatments. The coordinated modification of tRNAs by NSUN2 and METTL1, that mediates m⁷G methylation in tRNAs, was first 284 285 implicated in mediating sensitivity of Hela cells towards the cytotoxic agent 5-Fluorouracil (5-FU) ^{64,113,114}. 5-FU is commonly used to treat squamous cell carcinomas ¹¹⁵. Removal of 286 287 NSUN2 in mouse cutaneous tumours increases the number of undifferentiated stem and 288 progenitor cells; however, NSUN2-lacking tumour cells are also highly sensitive towards 289 cytotoxic drug treatment with 5-FU and cisplatin⁶⁴. This finding highlights the importance of 290 the dynamic deposition of m^5C into RNA. While stem and tumour-initiating cells lack NSUN2 to maintain a low translating stem cell state ^{64,116}, NSUN2 up-regulation, and thus 291 292 methylation of the RNA, is required to activate the appropriate survival pathways to regenerate the tumour after cytotoxic insult (*Figure 3*)⁶⁴. The high sensitivity of the tumour 293

cells towards drug treatment is angiogenin-depended and is therefore at least in part regulated
 via tRF formation ⁶⁴.

296

297 Activation of the PI3K signaling pathway in melanoma cells enhances the expression of $mcm^{5}s^{2}U$ writers ⁷⁹. The tRNA wobble modification $mcm^{5}s^{2}U$ is also required for specific 298 299 codon decoding during translation and sustains resistance in melanoma⁷⁹. Rewiring of protein synthesis during BRAF^{V600E}-driven resistance to targeted therapy induces a 300 301 translational bias for mcm⁵s²U-dependent codons, which are for instance found in the *Hifla* 302 mRNA. The enhanced synthesis of the HIF1 α protein thereby promotes glycolysis and maintains the metabolic requirements for the melanoma cells ⁷⁹. The resistant cells are re-303 sensitized to drug treatment through depletion of the mcm⁵s²U writers (*Figure 3*)⁷⁹. 304 305 Together, these recent studies highlight the importance of RNA modification pathways in 306 most aspects of tumourigenesis.

307

308 Summary and future prospective

309 RNA modifications are key players in regulating cell fate decision during development. More 310 recently, RNA modifications also emerged as an important regulator of cancer. Similar to 311 stem cells in most adult tissues, also tumour-initiating cells maintain the tumour in the long 312 term. An important feature of tumour-initiating cells is to efficiently adapt self-renewal, 313 proliferation and survival pathways to external cues. A dependency on RNA modifications to 314 switch cell fates, for example from a proliferating tumour cells to a quiescent tumour-315 initiating cell in response to chemotherapeutic drug treatment, may represent a window of 316 opportunity to specifically target tumour-initiating or resistant cell populations.

318 Cancer cells rapidly adapt to extreme environmental conditions by changes in specific 319 metabolic pathways and through translational control, mediating an adaptive response to oncogenic stress conditions ^{41,117}. RNA modifications emerged as one mechanistic link 320 321 between metabolism and enhanced codon-dependent translation of HIF1 α for instance to promote glycolytic metabolism ⁷⁹. Similarly, RNA modifications promote gene-specific 322 323 translation of one or several groups of tumour driver and suppressor genes. Thus, the 324 modulation or inhibition of RNA modification pathways offer novel therapeutic strategies to 325 target specific tumour populations, such as slow cycling tumour-initiating populations or 326 resistant tumour cells.

327

328 Depending on the tumour's heterogeneity, distinct RNA modifications patterns may be used 329 to identify tumour-initiating cells or to distinguish resistant from drug responsive tumour 330 populations. However, whether this could be exploited as a novel biomarker is difficult to 331 predict for several reasons. First, the tumour population of interest might be rather marked by 332 the absence than the presence of distinct modifications. Second, current methods to detect 333 RNA modifications suitable for easy, sensitive and reliable high throughput detection are 334 currently not available. Third, aberrant expression of an RNA modifier is often required for 335 the mis-expression of cell-type specific gene clusters. Thus, putative biomarkers may only be 336 suitable for distinct subtypes of tumours.

337

While aberrant expression of RNA modifying enzymes has now been described for most aspects of tumourigenesis, the precise contributions of the enzymes and respective modification to tumour initiation, growth, metastasis and resistance needs to be further investigated. Currently, it also remains unclear how specific modifications influence different tumour cell populations and how precisely they regulate survival, longevity and resistance. In

addition, the dynamic expression patterns of writer, reader and eraser proteins complicates the identification of the precise functional consequences of aberrant deposition of modifications on RNA metabolism and tumour cell fate decisions. Furthermore, with the exception of some tRNA modifications, it is currently largely unclear how different modifications influence each other and affect the binding to RNA-binding proteins. The development of new tools for the identification and quantification of RNA modification will be essential to further unearth their roles in the different steps of cancer development.

351 *References:*

- 3521Boccaletto, P. et al. MODOMICS: a database of RNA modification pathways. 2017353update. Nucleic Acids Res 46, D303-D307, doi:10.1093/nar/gkx1030 (2018).
- Helm, M. & Motorin, Y. Detecting RNA modifications in the epitranscriptome: predict
 and validate. *Nat Rev Genet* 18, 275-291, doi:10.1038/nrg.2016.169 (2017).
- 356 3 Natchiar, S. K., Myasnikov, A. G., Kratzat, H., Hazemann, I. & Klaholz, B. P.
 357 Visualization of chemical modifications in the human 80S ribosome structure. *Nature*358 551, 472-477, doi:10.1038/nature24482 (2017).
- 3594Sloan, K. E. *et al.* Tuning the ribosome: The influence of rRNA modification on360eukaryotic ribosome biogenesis and function. *RNA Biol* 14, 1138-1152,361doi:10.1080/15476286.2016.1259781 (2017).
- 362 5 Pan, T. Modifications and functional genomics of human transfer RNA. *Cell Res* 28, 395-404, doi:10.1038/s41422-018-0013-y (2018).
- 3646Rich, A. & RajBhandary, U. L. Transfer RNA: molecular structure, sequence, and365properties.AnnuRevBiochem45,805-860,366doi:10.1146/annurev.bi.45.070176.004105 (1976).
- 3677Schimmel, P. The emerging complexity of the tRNA world: mammalian tRNAs beyond368protein synthesis. Nat Rev Mol Cell Biol 19, 45-58, doi:10.1038/nrm.2017.77 (2018).
- 3698Adams, J. M. & Cory, S. Modified nucleosides and bizarre 5'-termini in mouse370myeloma mRNA. *Nature* 255, 28-33 (1975).
- 371 9 Desrosiers, R., Friderici, K. & Rottman, F. Identification of methylated nucleosides in
 372 messenger RNA from Novikoff hepatoma cells. *Proc Natl Acad Sci U S A* **71**, 3971373 3975 (1974).
- 37410Dubin, D. T. & Taylor, R. H. The methylation state of poly A-containing messenger375RNA from cultured hamster cells. *Nucleic Acids Res* 2, 1653-1668 (1975).
- Perry, R. P., Kelley, D. E., Friderici, K. & Rottman, F. The methylated constituents of L
 cell messenger RNA: evidence for an unusual cluster at the 5' terminus. *Cell* 4, 387394 (1975).
- 37912Schibler, U., Kelley, D. E. & Perry, R. P. Comparison of methylated sequences in
messenger RNA and heterogeneous nuclear RNA from mouse L cells. J Mol Biol 115,
695-714 (1977).
- Wei, C. M., Gershowitz, A. & Moss, B. Methylated nucleotides block 5' terminus of
 HeLa cell messenger RNA. *Cell* 4, 379-386 (1975).
- 38414Safra, M. *et al.* The m1A landscape on cytosolic and mitochondrial mRNA at single-
base resolution. *Nature* **551**, 251-255, doi:10.1038/nature24456 (2017).
- 38615Li, X. et al. Base-Resolution Mapping Reveals Distinct m(1)A Methylome in Nuclear-387and Mitochondrial-Encoded Transcripts. Mol Cell 68, 993-1005 e1009,388doi:10.1016/j.molcel.2017.10.019 (2017).
- 38916Mauer, J. et al. Reversible methylation of m6Am in the 5' cap controls mRNA390stability. Nature 541, 371-375, doi:10.1038/nature21022 (2017).
- 39117Delatte, B. *et al.* RNA biochemistry. Transcriptome-wide distribution and function of392RNA hydroxymethylcytosine. *Science* **351**, 282-285, doi:10.1126/science.aac5253393(2016).
- 39418Schwartz, S. et al. Transcriptome-wide mapping reveals widespread dynamic-395regulated pseudouridylation of ncRNA and mRNA. Cell 159, 148-162,396doi:10.1016/j.cell.2014.08.028 (2014).

- 397 19 Carlile, T. M. *et al.* Pseudouridine profiling reveals regulated mRNA 398 pseudouridylation in yeast and human cells. Nature 515, 143-146, 399 doi:10.1038/nature13802 (2014).
- 40020Yang, X. et al.5-methylcytosine promotes mRNA export NSUN2 as the401methyltransferase and ALYREF as an m(5)C reader. Cell Res 27, 606-625,402doi:10.1038/cr.2017.55 (2017).
- 40321Akichika, S. et al. Cap-specific terminal N (6)-methylation of RNA by an RNA404polymerase II-associated methyltransferase. Science, doi:10.1126/science.aav0080405(2018).
- Rintala-Dempsey, A. C. & Kothe, U. Eukaryotic stand-alone pseudouridine synthases RNA modifying enzymes and emerging regulators of gene expression? *RNA Biol* 14, 1185-1196, doi:10.1080/15476286.2016.1276150 (2017).
- 409
 23
 Roundtree, I. A., Evans, M. E., Pan, T. & He, C. Dynamic RNA Modifications in Gene

 410
 Expression Regulation. *Cell* **169**, 1187-1200, doi:10.1016/j.cell.2017.05.045 (2017).
- 411 24 Bokar, J. A., Rath-Shambaugh, M. E., Ludwiczak, R., Narayan, P. & Rottman, F.
 412 Characterization and partial purification of mRNA N6-adenosine methyltransferase
 413 from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J
 414 Biol Chem 269, 17697-17704 (1994).
- 415 25 Ke, S. *et al.* m6A mRNA modifications are deposited in nascent pre-mRNA and are 416 not required for splicing but do specify cytoplasmic turnover. *Genes Dev* **31**, 990-417 1006, doi:10.1101/gad.301036.117 (2017).
- 41826Bertero, A. *et al.* The SMAD2/3 interactome reveals that TGFbeta controls m(6)A419mRNA methylation in pluripotency. *Nature* 555, 256-259, doi:10.1038/nature25784420(2018).
- 421 27 Aguilo, F. *et al.* Coordination of m(6)A mRNA Methylation and Gene Transcription by
 422 ZFP217 Regulates Pluripotency and Reprogramming. *Cell Stem Cell* **17**, 689-704,
 423 doi:10.1016/j.stem.2015.09.005 (2015).
- 42428Barbieri, I. *et al.* Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-425dependent translation control. *Nature* **552**, 126-131, doi:10.1038/nature24678426(2017).
- 42729Jia, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-428associated FTO. Nature chemical biology 7, 885-887, doi:10.1038/nchembio.687429(2011).
- 43030Zheng, G. et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA431metabolism and mouse fertility.Mol Cell49, 18-29,432doi:10.1016/j.molcel.2012.10.015 (2013).
- 43331Wang, X. et al. N6-methyladenosine-dependent regulation of messenger RNA434stability. Nature 505, 117-120, doi:10.1038/nature12730 (2014).
- 43532Du, H. *et al.* YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment436of the CCR4-NOT deadenylase complex. Nat Commun 7, 12626,437doi:10.1038/ncomms12626 (2016).
- 438 33 Ivanova, I. *et al.* The RNA m(6)A Reader YTHDF2 Is Essential for the Post439 transcriptional Regulation of the Maternal Transcriptome and Oocyte Competence.
 440 *Mol Cell* 67, 1059-1067 e1054, doi:10.1016/j.molcel.2017.08.003 (2017).
- 44134Zhao, B. S. *et al.* m(6)A-dependent maternal mRNA clearance facilitates zebrafish442maternal-to-zygotic transition. Nature 542, 475-478, doi:10.1038/nature21355443(2017).

444 35 Shi, H. et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-445 modified RNA. Cell Res 27, 315-328, doi:10.1038/cr.2017.15 (2017). 446 36 Wang, X. et al. N(6)-methyladenosine Modulates Messenger RNA Translation 447 Efficiency. Cell 161, 1388-1399, doi:10.1016/j.cell.2015.05.014 (2015). 448 37 Yang, Y., Hsu, P. J., Chen, Y.-S. & Yang, Y.-G. Dynamic transcriptomic m6A decoration: 449 writers, erasers, readers and functions in RNA metabolism. Cell research 26, 616 -450 624, doi:doi.org/10.1038/s41422-018-0040-8 (2018). 451 Patil, D. P., Pickering, B. F. & Jaffrey, S. R. Reading m6A in the Transcriptome: m6A-38 452 Binding Proteins. Trends in Cell Biology 28, 113 127, 453 doi:doi.org/10.1016/j.tcb.2017.10.001 (2018). 454 Buszczak, M., Signer, R. A. & Morrison, S. J. Cellular differences in protein synthesis 39 455 regulate tissue homeostasis. Cell 159, 242-251, doi:10.1016/j.cell.2014.09.016 456 (2014). 457 40 Sonenberg, N. & Hinnebusch, A. G. Regulation of translation initiation in eukaryotes: 458 mechanisms and biological targets. Cell 136, 731-745, doi:10.1016/j.cell.2009.01.042 459 (2009). 460 41 Robichaud, N., Sonenberg, N., Ruggero, D. & Schneider, R. J. Translational Control in 461 Cancer. Cold Spring Harb Perspect Biol, doi:10.1101/cshperspect.a032896 (2018). 462 42 Chan, P. P. & Lowe, T. M. GtRNAdb 2.0: an expanded database of transfer RNA genes 463 identified in complete and draft genomes. Nucleic Acids Res 44, D184-189, 464 doi:10.1093/nar/gkv1309 (2016). 465 Dittmar, K. A., Goodenbour, J. M. & Pan, T. Tissue-specific differences in human 43 466 transfer RNA expression. PLoS Genet 2, e221, doi:10.1371/journal.pgen.0020221 467 (2006).468 44 Gingold, H. et al. A dual program for translation regulation in cellular proliferation 469 and differentiation. Cell 158, 1281-1292, doi:10.1016/j.cell.2014.08.011 (2014). 470 45 Kuhn, C. D. RNA versatility governs tRNA function: Why tRNA flexibility is essential 471 beyond the translation cycle. Bioessays 38, 465-473, doi:10.1002/bies.201500190 472 (2016). 473 46 Schaffrath, R. & Leidel, S. A. Wobble uridine modifications-a reason to live, a reason 474 to die?! RNA Biol 14, 1209-1222, doi:10.1080/15476286.2017.1295204 (2017). 475 47 Hanson, G. & Coller, J. Codon optimality, bias and usage in translation and mRNA 476 decay. Nat Rev Mol Cell Biol 19, 20-30, doi:10.1038/nrm.2017.91 (2018). 477 48 Chan, C. T. et al. Reprogramming of tRNA modifications controls the oxidative stress 478 response by codon-biased translation of proteins. Nat Commun 3, 937, 479 doi:ncomms1938 [pii]10.1038/ncomms1938 (2012). 480 49 Rezgui, V. A. N. et al. tRNA tK^{UUU}, tQ^{UUG}, and 481 tE^{UUC} wobble position modifications fine-tune protein translation by 482 promoting ribosome A-site binding. Proceedings of the National Academy of Sciences 483 **110**, 12289-12294, doi:10.1073/pnas.1300781110 (2013). 484 50 Ranjan, N. & Rodnina, M. V. tRNA wobble modifications and protein homeostasis. 485 Translation (Austin) 4, e1143076, doi:10.1080/21690731.2016.1143076 (2016). 486 51 Rapino, F., Delaunay, S., Zhou, Z., Chariot, A. & Close, P. tRNA Modification: Is Cancer 487 Having a Wobble? Trends Cancer 3, 249-252, doi:10.1016/j.trecan.2017.02.004 488 (2017).

- 489 52 Nedialkova, D. D. & Leidel, S. A. Optimization of Codon Translation Rates via tRNA
 490 Modifications Maintains Proteome Integrity. *Cell* 161, 1606-1618,
 491 doi:10.1016/j.cell.2015.05.022 (2015).
- 49253Zinshteyn, B. & Gilbert, W. V. Loss of a conserved tRNA anticodon modification493perturbscellularsignaling.*PLoSGenet***9**,e1003675,494doi:10.1371/journal.pgen.1003675 (2013).
- 49554Blanco, S. et al. Aberrant methylation of tRNAs links cellular stress to neuro-496developmental disorders. The EMBO journal **33**, 2020-2039,497doi:10.15252/embj.201489282 (2014).
- 49855Van Haute, L. *et al.* Deficient methylation and formylation of mt-tRNA(Met) wobble499cytosine in a patient carrying mutations in NSUN3. *Nat Commun* 7, 12039,500doi:10.1038/ncomms12039 (2016).
- 50156Nakano, S. *et al.* NSUN3 methylase initiates 5-formylcytidine biogenesis in human502mitochondrial tRNA(Met). Nature chemical biology **12**, 546-551,503doi:10.1038/nchembio.2099 (2016).
- 57 Haag, S. *et al.* NSUN3 and ABH1 modify the wobble position of mt-tRNAMet to 505 expand codon recognition in mitochondrial translation. *The EMBO journal*, 506 doi:10.15252/embj.201694885 (2016).
- 50758Kawarada, L. *et al.* ALKBH1 is an RNA dioxygenase responsible for cytoplasmic and508mitochondrial tRNA modifications. Nucleic Acids Res 45, 7401-7415,509doi:10.1093/nar/gkx354 (2017).
- 51059Thiaville, P. C. *et al.* Global translational impacts of the loss of the tRNA modification511t(6)A in yeast. *Microb Cell* **3**, 29-45, doi:10.15698/mic2016.01.473 (2016).
- 51260Tuorto, F. et al. The tRNA methyltransferase Dnmt2 is required for accurate513polypeptide synthesis during haematopoiesis. The EMBO journal,514doi:10.15252/embj.201591382 (2015).
- 51561Frye, M. & Blanco, S. Post-transcriptional modifications in development and stem516cells. Development 143, 3871-3881, doi:10.1242/dev.136556 (2016).
- 51762Guzzi, N. *et al.* Pseudouridylation of tRNA-Derived Fragments Steers Translational518Control in Stem Cells. *Cell*, doi:10.1016/j.cell.2018.03.008 (2018).
- 51963Schaefer, M. et al. RNA methylation by Dnmt2 protects transfer RNAs against stress-520induced cleavage.Genes Dev24, 1590-1595, doi:24/15/1590521[pii]10.1101/gad.586710 (2010).
- 52264Blanco, S. *et al.* Stem cell function and stress response are controlled by protein523synthesis. *Nature* **534**, 335-340, doi:10.1038/nature18282 (2016).
- 52465Wang, X. *et al.* Queuosine modification protects cognate tRNAs against ribonuclease525cleavage. *RNA*, doi:10.1261/rna.067033.118 (2018).
- 52666Tuorto, F. *et al.* Queuosine-modified tRNAs confer nutritional control of protein527translation. *The EMBO journal*, doi:10.15252/embj.201899777 (2018).
- 52867Torres, A. G., Batlle, E. & Ribas de Pouplana, L. Role of tRNA modifications in human529diseases. Trends in molecular medicine, doi:10.1016/j.molmed.2014.01.008 (2014).
- 530
 68
 Dai, D., Wang, H., Zhu, L., Jin, H. & Wang, X. N6-methyladenosine links RNA

 531
 metabolism to cancer progression. *Cell Death Dis* **9**, 124, doi:10.1038/s41419-017

 532
 0129-x (2018).
- Meacham, C. E. & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. *Nature* 501, 328-337, doi:10.1038/nature12624 (2013).

- 53570Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275-536291, doi:10.1016/j.stem.2014.02.006 (2014).
- 53771Delaunay, S. *et al.* Elp3 links tRNA modification to IRES-dependent translation of LEF1538to sustain metastasis in breast cancer. J Exp Med 213, 2503-2523,539doi:10.1084/jem.20160397 (2016).
- 54072Ladang, A. *et al.* Elp3 drives Wnt-dependent tumor initiation and regeneration in the541intestine. J Exp Med 212, 2057-2075, doi:10.1084/jem.20142288 (2015).
- 54273Close, P. *et al.* DERP6 (ELP5) and C3ORF75 (ELP6) regulate tumorigenicity and543migration of melanoma cells as subunits of Elongator. J Biol Chem 287, 32535-32545,544doi:10.1074/jbc.M112.402727 (2012).
- 54574Merlos-Suarez, A. *et al.* The intestinal stem cell signature identifies colorectal cancer546stem cells and predicts disease relapse. *Cell Stem Cell* 8, 511-524,547doi:10.1016/j.stem.2011.02.020 (2011).
- 548 75 Larsimont, J. C. et al. Sox9 Controls Self-Renewal of Oncogene Targeted Cells and 549 Initiation and Invasion. Cell Links Tumor Stem Cell 17, 60-73, 550 doi:10.1016/j.stem.2015.05.008 (2015).
- 55176Laguesse, S. et al. A Dynamic Unfolded Protein Response Contributes to the Control552ofCorticalNeurogenesis.Developmentalcell35,553-567,553doi:10.1016/j.devcel.2015.11.005 (2015).
- 55477Creppe, C. *et al.* Elongator controls the migration and differentiation of cortical555neurons through acetylation of alpha-tubulin. *Cell* **136**, 551-564,556doi:10.1016/j.cell.2008.11.043 (2009).
- 55778Kojic, M. *et al.* Elongator mutation in mice induces neurodegeneration and ataxia-558like behavior. *Nat Commun* **9**, 3195, doi:10.1038/s41467-018-05765-6 (2018).
- 55979Rapino, F. *et al.* Codon-specific translation reprogramming promotes resistance to
targeted therapy. *Nature*, doi:10.1038/s41586-018-0243-7 (2018).
- 56180Abbasi-Moheb, L. *et al.* Mutations in NSUN2 cause autosomal-recessive intellectual562disability. *Am J Hum Genet* **90**, 847-855, doi:S0002-9297(12)00199-1 [pii]
- 563 10.1016/j.ajhg.2012.03.021 (2012).
- 56481Khan, M. A. *et al.* Mutation in NSUN2, which Encodes an RNA Methyltransferase,565Causes Autosomal-Recessive Intellectual Disability. *Am J Hum Genet* **90**, 856-863,566doi:S0002-9297(12)00203-0 [pii]10.1016/j.ajhg.2012.03.023 (2012).
- 56782Martinez, F. J. *et al.* Whole exome sequencing identifies a splicing mutation in568NSUN2 as a cause of a Dubowitz-like syndrome. J Med Genet 49, 380-385,569doi:10.1136/jmedgenet-2011-100686 (2012).
- 570 83 Frye, M. *et al.* Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in 571 breast cancer. *Cancer Lett* (2009).
- 57284Lu, L., Zhu, G., Zeng, H., Xu, Q. & Holzmann, K. High tRNA Transferase NSUN2 Gene573Expression is Associated with Poor Prognosis in Head and Neck Squamous574Carcinoma. Cancer Invest **36**, 246-253, doi:10.1080/07357907.2018.1466896 (2018).
- 57585Signer, R. A., Magee, J. A., Salic, A. & Morrison, S. J. Haematopoietic stem cells576require a highly regulated protein synthesis rate. Nature 509, 49-54,577doi:10.1038/nature13035 (2014).
- 57886Signer, R. A. *et al.* The rate of protein synthesis in hematopoietic stem cells is limited579partly by 4E-BPs. *Genes Dev* **30**, 1698-1703, doi:10.1101/gad.282756.116 (2016).

- 580 87 Llorens-Bobadilla, E. *et al.* Single-Cell Transcriptomics Reveals a Population of
 581 Dormant Neural Stem Cells that Become Activated upon Brain Injury. *Cell Stem Cell*582 **17**, 329-340, doi:10.1016/j.stem.2015.07.002 (2015).
- 583 88 Wek, R. C., Jiang, H. Y. & Anthony, T. G. Coping with stress: eIF2 kinases and 584 translational control. *Biochem Soc Trans* **34**, 7-11, doi:10.1042/BST20060007 (2006).
- 58589Geula, S. *et al.* Stem cells. m6A mRNA methylation facilitates resolution of naive586pluripotency toward differentiation.*Science* **347**, 1002-1006,587doi:10.1126/science.1261417 (2015).
- 58890Batista, Pedro J. et al. m6A RNA Modification Controls Cell Fate Transition in589Mammalian Embryonic Stem Cells. Cell Stem Cell 15, 707-719,590doi:https://doi.org/10.1016/j.stem.2014.09.019(2014).
- 59191Huang, W. et al. Determination of DNA and RNA Methylation in Circulating Tumor592Cells by Mass Spectrometry. Anal Chem 88, 1378-1384,593doi:10.1021/acs.analchem.5b03962 (2016).
- 59492Zhang, C. et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-595dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA. Proc Natl596Acad Sci U S A 113, E2047-2056, doi:10.1073/pnas.1602883113 (2016).
- 59793Zhang, S. et al. m(6)ADemethylaseALKBH5MaintainsTumorigenicity of598GlioblastomaStem-likeCells by Sustaining FOXM1Expression and Cell Proliferation599Program. Cancer Cell **31**, 591-606 e596, doi:10.1016/j.ccell.2017.02.013 (2017).
- 60094Li, Z. et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-601MethyladenosineRNADemethylase.Cancercell**31**, 127-141,602doi:10.1016/j.ccell.2016.11.017 (2017).
- 60395Cui, Q. et al. m(6)A RNA Methylation Regulates the Self-Renewal and Tumorigenesis604ofGlioblastomaStemCells.Cellreports18,2622-2634,605doi:10.1016/j.celrep.2017.02.059 (2017).
- 606
 96
 Su, R. *et al.* R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA

 607
 Signaling. *Cell* **172**, 90-105.e123, doi:10.1016/j.cell.2017.11.031 (2018).
- 60897Liu, J. et al. m6A mRNA methylation regulates AKT activity to promote the609proliferation and tumorigenicity of endometrial cancer. Nature cell biology 20, 1074–6101083, doi:DOI: 10.1038/s41556-018-0174-4 (2018).
- 611 98 Vu, L. P. *et al.* The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls
 612 myeloid differentiation of normal hematopoietic and leukemia cells. *Nature*613 *medicine* 23, 1369-1376, doi:10.1038/nm.4416 (2017).
- 614 99 Weng, H. *et al.* METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and
 615 Promotes Leukemogenesis via mRNA m⁶A Modification. *Cell Stem Cell*616 **22**, 191-205.e199, doi:10.1016/j.stem.2017.11.016 (2018).
- 617 100 Lin, S., Choe, J., Du, P., Triboulet, R. & Gregory, R. I. The m(6)A Methyltransferase
 618 METTL3 Promotes Translation in Human Cancer Cells. *Mol Cell* 62, 335-345,
 619 doi:10.1016/j.molcel.2016.03.021 (2016).
- Huang, H. *et al.* Recognition of RNA N(6)-methyladenosine by IGF2BP proteins
 enhances mRNA stability and translation. *Nature cell biology* 20, 285-295,
 doi:10.1038/s41556-018-0045-z (2018).
- 623102Deng, X. et al. RNA N(6)-methyladenosine modification in cancers: current status and624perspectives. Cell Res 28, 507-517, doi:10.1038/s41422-018-0034-6 (2018).

- 625 103 Popis, M. C., Blanco, S. & Frye, M. Posttranscriptional methylation of transfer and 626 ribosomal RNA in stress response pathways, cell differentiation, and cancer. Curr 627 Opin Oncol 28, 65-71, doi:10.1097/CCO.000000000000252 (2016).
- 628 104 Dachs, G. U. & Tozer, G. M. Hypoxia modulated gene expression: angiogenesis, 629 metastasis and therapeutic exploitation. Eur J Cancer 36, 1649-1660 (2000).
- 630 105 Rankin, E. B. & Giaccia, A. J. Hypoxic control of metastasis. Science 352, 175-180, 631 doi:10.1126/science.aaf4405 (2016).
- 632 Chionh, Y. H. et al. tRNA-mediated codon-biased translation in mycobacterial 106 633 hypoxic persistence. Nat Commun 7, 13302, doi:10.1038/ncomms13302 (2016).
- 634 107 Flores, J. V. et al. Cytosine-5 RNA Methylation Regulates Neural Stem Cell 635 Differentiation and Motility. Stem Cell Reports 8, 112-124, 636 doi:10.1016/j.stemcr.2016.11.014 (2017).
- 637 Yi, J. et al. Overexpression of NSUN2 by DNA hypomethylation is associated with 108 638 metastatic progression in human breast cancer. Oncotarget 8, 20751-20765, 639 doi:10.18632/oncotarget.10612 (2017).
- 640 109 Goodarzi, H. et al. Endogenous tRNA-Derived Fragments Suppress Breast Cancer 641 Progression via YBX1 Displacement. Cell 161, 790-802, 642 doi:10.1016/j.cell.2015.02.053 (2015).
- 643 110 Chen, M. et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver 644 cancer progression through YTHDF2-dependent posttranscriptional silencing of 645 SOCS2. *Hepatology* **67**, 2254-2270, doi:10.1002/hep.29683 (2018).
- 646 111 Ma, J.-z. et al. METTL14 suppresses the metastatic potential of hepatocellular 647 carcinoma by modulating N6-methyladenosine-dependent primary MicroRNA 648 processing. *Hepatology* **65**, 529-543, doi:doi:10.1002/hep.28885 (2017).
- 649 112 Alarcon, C. R., Lee, H., Goodarzi, H., Halberg, N. & Tavazoie, S. F. N6-650 methyladenosine marks primary microRNAs for processing. Nature 519, 482-485, 651 doi:10.1038/nature14281 (2015).
- 652 113 Okamoto, M. et al. tRNA Modifying Enzymes, NSUN2 and METTL1, Determine 653 Sensitivity to 5-Fluorouracil in HeLa Cells. PLoS Genet 10, e1004639, 654 doi:10.1371/journal.pgen.1004639 (2014).
- Alexandrov, A., Martzen, M. R. & Phizicky, E. M. Two proteins that form a complex 655 114 656 are required for 7-methylguanosine modification of yeast tRNA. RNA 8, 1253-1266 657 (2002).
- 658 Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of action 115 659 and clinical strategies. Nat Rev Cancer 3, 330-338, doi:10.1038/nrc1074 (2003).
- 660 116 Blanco, S. et al. The RNA-methyltransferase Misu (NSun2) poises epidermal stem 661 cells to differentiate. PLoS Genet 7, e1002403, doi:10.1371/journal.pgen.1002403
- 662 PGENETICS-D-11-00619 [pii] (2011).
- 663 Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even 117 664 warburg did not anticipate. Cancer Cell 21, 297-308, doi:10.1016/j.ccr.2012.02.014 665 (2012).
- 666 667 668
- 669
- 670

671 Acknowledgements

- 672 M.F. is supported by a Cancer Research UK Senior Fellowship (C10701/A15181), the
- 673 European Research Council (ERC; 310360), and the Medical Research Council UK
- 674 (MR/M01939X/1). S.D. is funded by an EMBO Long-Term Fellowship. Part of this work
- 675 was carried out in the framework of the European COST action EPITRAN 16120.
- 676
- 677
- 678
- 679
- 680
- 681

682 Figure Legends

683 Figure 1: RNA modifications and their writer proteins. a, Schematic representation of a 684 tRNA molecule and examples of RNA modifications and their modifying enzymes. 685 Modifications at the wobble position are highlighted in purple. **b**, Schematic representation of 686 the modifications internal to messenger RNA. Some of these modifications are enriched in 687 the 5'UTR, the coding sequence or the 3'UTR of the mRNA. $m^{6}A$ is catalyzed by a complex 688 of multi-proteins containing enzymes and accessory proteins. Abbreviations: m¹A: N1-689 methyladenosine; Ψ : pseudouridine; rT: ribothimidine; m⁵C: 5-methylcytosine; D: 690 dihydrouridine; m^7G . 7-methylguanosine; $m^{1}I$: 1-methylinosine; i⁶A: N6-691 isopentenyladenosine; m^1G : 1-methylguanosine; yW: wybutosine; t^6A : N6-692 threonylcarbamoyladenosine; I: inosine; Gm: 2'-O-methylguanosine; Cm: 2'-O mcm^5s^2U . $mcm^{5}U$, 693 methylcytidine; 5-methoxycarbonylmethyluridine; 5methoxycarbonylmethyl-2-thiouridine; ncm⁵U: 5-carbamoylmethyluridine; ncm⁵Um: 5-694 carbamoylmethyl-2'-O-methyluridine; s²U: 2-thiouridine; Am: 2'-O-methyladenosine; m²G: 695 N2-methylguanosine; m⁶Am: N6,2'-O-dimethyladenosine; hm⁵C: 5-hydroxymethylcytidine. 696 697 PUS: Pseudouridylate Synthase; TRUB2: TruB Pseudouridine Synthase Family Member 2; 698 NSUN2, NOP2/Sun RNA methyltransferase family member 2; WDR4, WD repeat domain 4; 699 DNMT2, DNA methyltransferase 2; TRM or TRMT, tRNA methyltransferase; ELP, 700 Elongator protein homolog; CTU: Cytosolic Thiouridylase; ALKBH: AlkB Homolog 8, 701 TRNA Methyltransferase; ADAT3, adenosine deaminase acting on tRNA 3; TET: Tet 702 Methylcytosine Dioxygenase; DKC1: Dyskerin Pseudouridine Synthase 1; RBM: RNA 703 Binding Motif Protein; ZC3H13: Zinc Finger CCCH-Type Containing 13; VIRMA: Vir Like 704 m⁶A Methyltransferase Associated; WTAP: WT1 Associated Protein; METTL: 705 Methyltransferase Like.


Figure 2: RNA modifications regulate gene expression programs. a, m⁶A is deposited by 707 708 a 'writer' multi-protein complex (i.e. METTL3, METTL14) and removed by 'eraser' 709 demethylases (i.e. FTO, ALKBH5), which induce stabilization or decay of the target mRNA. 710 In the cytoplasm, the mRNA modifications are recognized by 'reader' proteins. b, The 711 deposition of mcm⁵s²U modification is required for the optimal base pairing between tRNA^{UUU}, tRNA^{UUC}, tRNA^{UUG} and tRNA^{UCU} and the corresponding codons enriched in 712 713 specific mRNA targets (i.e. Sox9, Dek, Lef1). c, tRNAs are methylated by NSUN2 in the 714 nucleoli. The m⁵C modification reduces the affinity to the endonuclease angiogenin in the cytoplasm. m⁵C maintains global protein synthesis. Loss of m⁵C alters the biogenesis of 715 716 tRNA-derived small non-coding RNA fragments (tRFs), which inhibit de novo protein 717 synthesis.

718

719 Figure 3: Roles of RNA modifications in cancer. RNA modifications are involved in multiple aspects of tumourigenesis. $mcm^{5}s^{2}U$ is required for Wnt-driven colorectal cancer 720 721 (CRC) initiation, development of lung metastasis from PyMT breast tumours, and PI3K pathway-addicted resistance to therapy in melanoma. m⁵C levels are high in committed 722 723 progenitors of skin tumours, and it is crucial for resistance to drug treatment. Lack of NSUN2 724 increases the number of undifferentiated stem and progenitor cells. Elevated levels of m⁶A on 725 specific mRNA inhibit metastasis in hepatocellular carcinoma (HCC) and growth in 726 glioblastoma tumours. m⁶A is also advantageous for the maintenance of a cell-727 undifferentiated state in leukemia and promotes tumour initiation. In breast cancer cell lines, 728 up-regulation of ALKBH5 enhances tumour initiation capacity.

729

Figure 1






Figure 3

